论文部分内容阅读
尽管手术和放疗取得很大进步,但子宫癌的预后仍很差,这表示传统的手术和放疗方法并未能提高治愈率、降低死亡率和改善患者的生活状况。为此提出一种设想,即把烷化剂与某种能选择地集中在靶器官的物质结合在一起,以提高组织浓度、减少周身毒性反应。17β-雌二醇磷酸酯和氮芥类结合物(Estracyt)即属这类药物。它已成功地用于治疗对其他化疗抗药的晚期前列腺癌。但对Estracyt的代谢了解的很少,只知酯键水解所释放的磷酸雌二醇和氮芥基团均很少;临床用于治疗前列腺癌时,既使长时间、大剂量也很少出现雌激素的副作用;男、
Despite the great advances in surgery and radiotherapy, the prognosis of uterine cancer is still poor, suggesting that traditional surgical and radiotherapy methods do not increase the cure rate, reduce mortality and improve the patient’s condition. To this end, a proposal was made that the alkylating agent should be combined with some substance that can be selectively concentrated in the target organ so as to increase the tissue concentration and reduce the perinatal toxicity. Estradiol 17β-estradiol phosphate conjugate (Estracyt) that is such drugs. It has been successfully used to treat advanced prostate cancer that is resistant to other chemotherapies. However, little is known about the metabolism of Estracyt. Only few estrone and nitrogen mustard groups released by ester bond hydrolysis are found. For clinical use in the treatment of prostate cancer, Hormonal side effects; male,